Skip to main content
Journal of Ocular Pharmacology and Therapeutics logoLink to Journal of Ocular Pharmacology and Therapeutics
. 2020 Jul 24;36(6):484. doi: 10.1089/jop.2019.0146.correx

Correction to: Matrix Metalloproteinases and Glaucoma Treatment, by Weinreb, R.N., Robinson, M.R., Dibas, M. and Stamer, W.D. J Ocul Pharmacol Ther 2020;36(4):208–228. DOI: 10.1089/jop.2019.0146

PMCID: PMC7416548  PMID: 32721205

In the MAY 2020 issue of Journal of Ocular Pharmacology and Therapeutics (vol. 36, no. 4; 208–222) the article entitled Matrix Metalloproteinases and Glaucoma Treatment by Weinreb et al. requires correction. The legend for Figure 8 has been updated.

On page 222, the legend for Figure 8 originally read:

FIG. 8. Bimatoprost SR is a first-in-class, sustainedrelease, bimatoprost implant that is administered intracamerally. (A) Photograph of an implant (10-mg dose strength; arrow) superimposed on an image of a dime. The implant is similar in size to the ‘‘i’’ in Liberty on the dime; the shape is cylindrical (radius*200 mm, length*1.1 mm). (B) Photograph of a single-use, 28-gauge applicator used for implant administration.

This has been corrected to read:

FIG. 8. Bimatoprost SR is a first-in-class, sustainedrelease, bimatoprost implant that is administered intracamerally. (A) Photograph of an implant (10-mg dose strength; arrow) superimposed on an image of a dime. The implant is similar in size to the ‘‘i’’ in Liberty on the dime; the shape is cylindrical (diameter*200 mm, length*1.1 mm). (B) Photograph of a single-use, 28-gauge applicator used for implant administration.

The online version of the article has been corrected. The authors apologize for the error.


Articles from Journal of Ocular Pharmacology and Therapeutics are provided here courtesy of Mary Ann Liebert, Inc.

RESOURCES